Activity Details (PDF Format)
	Course Materials (PDF Format)
	Additional Q&A
	Participate in Archived Online Activity
	Complete Post-Test/ Print CE Certificate
	Faculty
	Statement of Need
	Activity Goal
	Learning Objectives
	Target Audience
	Commercial Support
	Credit Information

CMEO Webcast

Premiere Date: Saturday, March 29, 2008

This activity offers CE credit for:

1. Physicians (ACCME/AMA PRA Category 1)
2. Nurses (CNE)
3. Pharmacists (ACPE)

All other clinicians will either receive a CME Attendance Certificate or may choose any of the types of CE credit being offered.
Credit Expiration Date:
Sunday, March 29, 2009

Faculty

MODERATOR: Christopher P. Cannon, MD Senior Investigator, TIMI Study Group Brigham and Women's Hospital Associate Professor of Medicine Harvard Medical School Boston, MA

Jeffrey L. Anderson, MD, FACC, FAHA, MACP Associate Chief of Cardiology Intermountain Medical Center Co-Director of Cardiac Research Professor of Internal Medicine University of Utah Salt Lake City, UT

Robert A. Harrington, MD Professor of Medicine, Division of Cardiology Duke University Medical Center Director, Duke Clinical Research Institute Durham, NC

Statement of Need

Acute coronary syndrome (ACS) affects more than 1.5 million people in the United States each year, and is associated with an increased risk of cardiac death.(1) Prevention of cardiac events in patients with ACS and those with prior myocardial infarction (MI) or stroke is crucial to improving outcomes and preventing death. Yet, almost half of all patients are under-recognized and not adequately managed. The American College of Cardiology/American Heart Association (ACC/AHA) have recently published new treatment guidelines for ACS, yet even when guidelines are incorporated in practice, some issues remain controversial. For instance, dosing and timing of the administration of antithrombotic therapies is not consistent and these factors can impact outcome.(2) Also, clinicians need to know the importance of risk stratification in the management of ACS. In addition, short-term and long-term management strategies for ACS may differ, and there is not yet consensus in the field regarding best practices. Although current antithrombotic agents are effective, there is room for improvement in outcomes. Promising new agents, including PY212 inhibitors, thrombin receptor antagonists, and Factor Xa inhibitors may play a key role in improving patient care. Faculty in this interactive, case-based symposium will translate the latest evidence on treatment guidelines and emerging management strategies to improve practice, individualize treatments, and optimize outcomes of patients with ACS.

---

1. Kaiyala E, et al. Emerg Med 2004;36:20-38.
2. Giugliano R, et al. Am Heart J 2006;149:994-1002.
3. Wiviott SD, et al. N Engl J Med 2007;357:2001-2015.

This event is not part of the official ACC Annual Scientific Session and/or the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit as planned by their Program Committees.

Activity Goal

To provide an overview of current and emerging treatment strategies for patients with acute coronary syndrome.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Describe the impact of treatment selection, dosing, and timing of antiplatelet therapies on overall outcomes of patients with acute coronary syndrome.
• Recognize the role of antithrombotic therapy in the prevention and management of acute coronary syndrome according to ACC/AHA guidelines.
• Evaluate emerging therapies in the management of patients with acute coronary syndrome.

Target Audience

Cardiologists, physician assistants, nurses, nurse practitioners, pharmacists, and other clinicians who treat patients with acute coronary syndrome.

Commercial Support

CME Outfitters, LLC, gratefully acknowledges an educational grant from Schering-Plough Corporation in support of this CE activity.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CME Outfitters, LLC, designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Note to Physician Assistants: AAPA accepts Category I credit from AOACCME, Prescribed credit from AAFP, and AMA Category I CME credit for the PRA from organizations accredited by ACCME.

CNE Credit (Nurses):
CME Outfitters, LLC, is an approved provider of continuing nursing education by the New York State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

It has been assigned code 6WASUP-PRV-0629. 2.0 contact hours will be awarded upon successful completion.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 2.0 contact hours (0.2 CEUs)
Universal Program Number: 376-000-08-005-L01-P (live presentation) 376-000-08-005-H01-P (recorded programs)

Post-tests, credit request forms, and activity evaluations can be completed online at www.CMEoutfitters.com/test (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required).

Questions about this CE activity? Call us at 877.CME.PROS (877.263.7767).

MM-014-032908-18